Abstract: A pressed biomass component is disclosed. The pressed biomass component includes plant or animal material that is compressed by a press plate apparatus by application of pressure within a range of 1000 to 36000 pounds per square inch (PSI). The pressed biomass component is a resultant of the application of the pressure to the plant or animal material and typically has a weight of 0.5-10 grams. The pressed biomass component of claim 1 may be formed in a disc shape including a curved perimeter, a top surface and a bottom surface oriented in parallel with the top surface; thus, resembling a coin. The application of pressure to the press plate apparatus forms the pressed biomass component to support a desired burn time when placed on a heating apparatus. The heating apparatus often includes a ceramic bulb having a wattage within a wattage range of 50 w-150 w.

Abstract: Disclosed herein are lipid nanoparticles comprising 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000](DSPE-PEG2000), compositions including such lipid nanoparticles, and methods of treatment using such lipid nanoparticles and compositions.

Abstract: The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.

Abstract: The hollow particles according to the present invention has a balloon structure which includes a cavity inside a shell, and include convex portions with a size of 3 to 100 nm on the surface. The particles have a true specific gravity of 0.3 to 3.0 g/cm3, a specific surface area (m2/cm3) per unit volume calculated by a BET method of not less than 0.5 and less than 60, and an average particle diameter (d1) of 1 to 20 ?m. Cosmetics containing such hollow particles have a soft texture property similar to plastic beads.

Abstract: Provided is a process for preparing an alcoholic solution of a polyvinylpyridine polymer having biocidal and biocompatibility properties. The alcoholic solution is ready-to-graft in order to confer biocidal properties to various surfaces and to prevent biofilm formation on such surfaces. Also provided are methods of using the alcoholic solution, such as for controlling the growth of bacteria, fungi and/or viruses, and/or for preventing digestion of wood cellulose by wood-boring insects.

Abstract: Disclosed are conjugates between stanozolol and hyaluronic acid or a hyaluronic acid salt, characterised in that stanozolol is conjugated with the carboxyl group of hyaluronic acid or the hyaluronic acid salt via a spacer that forms an ester bond with the hydroxyl group of stanozolol and an ester or amide bond with the carboxyl group of hyaluronic acid or the hyaluronic acid salt. The conjugates according to the invention are useful to prepare hydrogels, injectable hydrogels, hydrogels for external use, creams, lotions, foams, aqueous solutions for intra-articular use, emulsions for ophthalmic use, eyedrops, scaffolds, artificial tissues and culture media.

Abstract: Zeinmersomes (ZMS) comprising zein, a phospholipid and a PEG-polymer are formulated to encapsulate a drug of interest. Olmesartan medoxomil (OM) is encapsulated in the ZMS (OM-ZMS) for oral administration and taken up by the liver where OM diffuses from the ZMS nanocarrier. OM concentrations in liver were at least 8 times higher than that measured in plasma. Established fibrosis was reversed in a thioacetamide-induced rat model of human chronic hepatic fibrosis. The OM-ZMS provides a hepatic drug delivery system that reduces the potential of side-effects caused by OM, including OM-associated sprue-like enteropathy, to treat chronic hepatic fibrosis and associated duodenal changes.

Abstract: A method for preparing a composition of matter, the method including: 1) mixing a Zn(NO3)2 solution, a Hg(NO3)2 solution, and a mercaptopropionic acid solution, thereby yielding a precursor solution of Zn2+—Hg2+-mercaptopropionic acid; dissolving a selenium powder and a NaBH4 solid in water thereby yielding a NaHSe slurry; mixing the precursor solution and the NaHSe slurry thereby yielding zinc-mercury-selenium (ZnHgSe) quantum dot; 2) preparing a drug delivery system including dextran-magnetic layered double hydroxide-fluorouracil (DMF); binding the drug delivery system and the ZnHgSe quantum dot in a mass ratio of 1:1-3; and grinding the drug delivery system including the ZnHgSe quantum dot (QD) thereby yielding powders; and 3) dissolving the powders in absolute ethyl alcohol thereby yielding a first suspension; ultrasonically dispersing the first suspension thereby yielding a second suspension, magnetically separating the second suspension thereby yielding a solid product, centrifuging and washing the soli

Abstract: The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

Abstract: The present disclosure relates to naltrexone sustained release microparticle delivery systems for the treatment of diseases ameliorated by naltrexone. The injectable microparticle delivery system includes naltrexone encapsulated in biodegradable microparticles administered in a pharmaceutically acceptable vehicle.

Abstract: The present disclosure relates to anti-fouling and/or anti-thrombotic medical devices, methods for reducing fouling and/or thrombosis associated with medical devices, and methods for coating substrates to reduce fouling and/or thrombosis. Certain embodiments of the present disclosure provide an anti-fouling and/or anti-thrombotic medical device comprising a metallic substrate comprising a hyperbranched polyglycerol coating.

Abstract: An inorganic composition that is useful as an active ingredient for pharmaceuticals and has excellent stability comprises hydrozincite-containing zinc carbonate hydroxide hydrate produced by drying a precipitate. The precipitate is obtained by adding aqueous zinc nitrate solution, aqueous zinc sulfate solution or aqueous zinc chloride solution and aqueous sodium hydroxide solution dropwise to aqueous sodium hydrogen carbonate solution, a pH of the aqueous sodium hydrogen carbonate solution being maintained within a range of 6.5 to 9 by means of a pH controller. The hydrozincite-containing zinc carbonate hydroxide hydrate has an amount of dissolved Zn2+ ions of not less than 0.1 ?g/m2 but not more than 7.33 ?g/m2 and pH of not less than 7.2 and less than 8.3 after a dissolution test using stirring method.

Abstract: Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

Abstract: The instant disclosure generally relates to a dual component hair coloring composition for coloring mammalian or synthetic keratin fibers, the composition comprising composition A comprising a cationic polymer, pigment microparticles and an aqueous medium, and comprising composition B comprising an anionic polymer, aqueous medium and optional cross linking agent. Optionally or alternatively composition B may contain pigment particles. The cationic and anionic polymers are at least partially soluble in the medium and the pigment microparticles are dispersed therein. The hair coloring composition forms a dual layer coating upon application to keratin fibers such as hair and has a substantially permanent pigment lastingness following development (setting); minimally alters the keratin fibers, upon application; and substantially eliminates development time. Methods of using such compositions are also described herein.

Abstract: Two vial containing kits containing aspirin for intravenous administration are disclosed. The first vial contains a lyophilized mixture of aspirin in crystalline form, a bulking agent such as mannitol and a surfactant. The second vial includes an aqueous diluent such as water for injection and a basifying agent such as Tris.

Abstract: The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.

Abstract: Provided are a method for rapidly producing a calcium phosphate molded article having high strength with high shaping precision, a calcium phosphate molded article produced by the method, and a material for transplantation. Disclosed is a method for producing a calcium phosphate molded article, the method including: step (a) of forming a layer containing a calcium phosphate powder having a ratio of the numbers of atoms of Ca/P of 1.4 to 1.8 on a substrate; and step (b) of producing a calcium phosphate molded article by jetting an organic acid solution having a pH of 3.5 or lower and including an organic acid whose calcium salt has a solubility in water of 1 g/100 mL or less, through a nozzle unit into a liquid droplet state, thereby dropping the organic acid solution onto the layer containing a calcium phosphate powder formed in step (a).

Abstract: Disclosed herein are tissue scaffold materials with microspheres of one density embedded in hydrogel of a different density. The disclosed materials have improved ability to facilitate cellular invasion and vascularization for wound healing and tissue regeneration. The inventors have found that materials having components with different densities promotes invasion of cells, including desirable cells such as fibroblasts and endothelial precursor cells, into the scaffold.

Abstract: The invention relates to nanoparticles for the systemic or topical delivery of lipophilic diagnostic or therapeutic agents to a subject in need thereof. The nanoparticles of the invention comprise a water soluble polymer and at least one of a biocompatible lipid and a lipophilic agent. The invention further relates to ophthalmic treatment using the nanoparticles of the invention. In addition, the invention pertains to compositions and formulations comprising the nanoparticle of the invention. Such formulation may be an eye drop formulation.

Abstract: Provided herein are microencapsulated chitosan materials and formulations containing same, methods of making such formulations, and methods of using such formulations. Application of a microencapsulation coating on chitosan materials and formulations containing same renders possible the use of chitosan materials for different, novel chitosan-based dietary applications with the primary aim to decrease intestinal absorption of fat and enhance overall health, without interfering with or reducing food palatability. The present invention provides methods to microencapsulate highly effective chitosan or chitosan salts to moderate their interaction with food components and mask any off-flavors and off-tastes but allow rapid chitosan solubilization under gastric acid conditions and simultaneous binding of ingested lipids. Chitosan contemplated for use herein is preferably of high quality with high fat-binding capacity, and its source is preferably of crustacean origin.